CRDMO business model drives sustainable high growth
3
"R" 28%↑[2]
"D" 42%↑[2]
"M"34%↑[2]
4
349,704 compounds
5,485 compounds "R+"
99[1]
1,627Preclinical & Phase I
39[1]
288 Phase II
8[1]
52 Phase III
8[1]
[1]
number of molecules were moved to next stage and kept
43Commercial
in WuXi Chemistry within past 12 months
[2]
increase rate vs. the number of end of 2021 June
Number of Compound Delivered by WuXi Chemistry C"R"DMO
+28%
+38%
355,189
278,105
201,516
2019.07-2020.06
2020.07-2021.06
2021.07-2022.06
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 09:41:05 UTC.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .